2YP Stock Chart & Stats
€1.37
-€0.01(-0.54%)
At close: 4:00 PM EDT
€1.37
-€0.01(-0.54%)
Day’s Range― - ―
52-Week Range€0.86 - €2.94
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€114.72M
Enterprise Value€213.72M
Total Cash (Recent Filing)€103.44M
Total Debt (Recent Filing)€169.98M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Nov 10, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.68
Shares Outstanding75,256,380
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.68
Price to Sales (P/S)0.54
P/FCF Ratio-704.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.63Price Target Upside18.78% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-0.04
Revenue Forecast (FY)€217.49M
Bulls Say, Bears Say
Bulls Say
Debt EliminationEliminating approximately $160 million of debt materially strengthens financial flexibility and removes about $19 million of annual GAAP interest expense. The lower fixed-cost burden should preserve more cash for product investment, customer support, and execution through the company’s transition.
Improved Cash GenerationThe shift to positive operating and free cash flow is a meaningful improvement in internal funding capacity. If maintained, stronger cash generation can support ongoing technology investment and reduce reliance on external capital, although its durability depends on eventual improvement in reported profitability.
Operating Cost DisciplineLower operating expenses and progress on Project Nexus indicate tangible cost discipline within the software and analytics business. Sustained savings can improve operating leverage as the company scales its core platform, helping offset transition costs and supporting a more durable path toward profitability.
Bears Say
Persistent Large LossesVery large ongoing losses show that improved gross margin is not yet translating into sustainable earnings. Continued cost structure or non-operating burdens could consume the benefit of positive cash flow, weaken the equity cushion over time, and limit the company’s ability to self-fund growth.
Migration-Related ARR RiskMigration-related downsell, churn, and at-risk ARR create a material threat to recurring software revenue and customer expansion. Losses at this level can reduce the installed revenue base, weaken visibility for future growth, and make it harder for operating leverage to emerge.
Revenue And Margin PressureLowered full-year guidance and an expected sub-50% gross margin indicate that the transition is weighing on near- to medium-term operating performance. Vitalware’s removal, migration costs, and weaker services expectations may constrain growth and delay meaningful profitability improvement.
Health Catalyst News
2YP FAQ
What was Health Catalyst’s price range in the past 12 months?
Health Catalyst lowest stock price was €0.85 and its highest was €2.94 in the past 12 months.
What is Health Catalyst’s market cap?
Health Catalyst’s market cap is €114.72M.
When is Health Catalyst’s upcoming earnings report date?
Health Catalyst’s upcoming earnings report date is Nov 10, 2026 which is in 20 days.
How were Health Catalyst’s earnings last quarter?
Health Catalyst released its earnings results on Aug 06, 2026. The company reported €0.036 earnings per share for the quarter, beating the consensus estimate of €0.027 by €0.009.
Is Health Catalyst overvalued?
According to Wall Street analysts Health Catalyst’s price is currently Undervalued.
Does Health Catalyst pay dividends?
Health Catalyst does not currently pay dividends.
What is Health Catalyst’s EPS estimate?
Health Catalyst’s EPS estimate is -0.04.
How many shares outstanding does Health Catalyst have?
Health Catalyst has 75,256,380 shares outstanding.
What happened to Health Catalyst’s price movement after its last earnings report?
Health Catalyst reported an EPS of €0.036 in its last earnings report, beating expectations of €0.027. Following the earnings report the stock price went down -28.365%.
Which hedge fund is a major shareholder of Health Catalyst?
Currently, no hedge funds are holding shares in DE:2YP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Health Catalyst Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€1.63 (18.78% Upside)
€1.63 (18.78% Upside)
Blogger Sentiment
Neutral
DE:2YP Sentiment 100%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth €93.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-43.93%
12-Months-Change
Fundamentals
Return on Equity
-129.70%
Trailing 12-Months
Asset Growth
-41.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Health Catalyst
Health Catalyst, Inc. equips healthcare providers with crucial data and analytical technologies, alongside specialized services. Their extensive product line features a robust, enterprise-level data and analytics platform designed specifically for the healthcare sector. They additionally offer advanced artificial intelligence (AI) and data science solutions that integrate AI seamlessly into existing business intelligence tools, thereby enhancing analytical precision. The company's services also cover population health management, which identifies areas for improvement throughout the patient care journey, offering actionable recommendations and automated processes. For financial effectiveness, they provide critical insights into cost analysis, workforce efficiency, and revenue maximization. Moreover, Health Catalyst contributes to improving quality and safety by leveraging clinical and patient safety data, sophisticated analytics, and expert consulting. They also facilitate a national data ecosystem, promoting collaborative thought leadership and shared knowledge to generate groundbreaking insights that redefine healthcare delivery. Established in 2008 and based in South Jordan, Utah, the company was formerly known as HQC Holdings, Inc. before officially becoming Health Catalyst, Inc. in March 2017.
2YP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated meaningful strategic progress: a completed divestiture that eliminated debt and interest costs, cost reductions via Project Nexus, a Q2 revenue beat and adjusted EBITDA at the high end of guidance, and continued investments in technology and AI. However, the near-term picture is constrained by the loss of Vitalware's revenue/EBITDA contribution, persistent migration-related churn and at-risk ARR, margin pressure from dual operating costs during migrations, and a lowered full-year revenue/EBITDA outlook. Management frames these as deliberate, multiyear transformation actions that improve the capital structure and position the company for long-term growth while acknowledging short-term revenue and margin headwinds.View all DE:2YP earnings summaries2YP Stock 12 Month Forecast
Average Price Target
€1.63
▲(18.78% Upside)
Technical Analysis
Evolent Health
―
Phreesia
―
Privia Health Group
―
Definitive Healthcare Corp
―
Waystar Holding Corp.
―